News Report · Neurology

Who Qualifies for Lecanemab: Eligibility Criteria and Amyloid PET

June 12, 2026

Clinical Perspective

Lecanemab is indicated for patients with early Alzheimer disease who meet specific eligibility criteria based on amyloid PET imaging. The data supports a 27% reduction in amyloid PET positivity, which may facilitate earlier diagnosis and treatment. How can clinicians best integrate amyloid PET imaging into routine practice for AD diagnosis?

Dr. Vikram Patel · Neurology

Lecanemab reduced amyloid PET positivity in Alzheimer disease patients by 27% versus placebo in a pivotal trial ^[1].

Clinical Context

Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss, affecting millions worldwide. In 2021, approximately 57 million people lived with dementia, with AD accounting for 60-70% of these cases ^[2]. Current treatment options primarily focus on symptomatic relief, but there is a growing need for therapies that address underlying pathologies, such as amyloid plaques. Recent developments in amyloid PET imaging have enhanced diagnostic accuracy, but coverage criteria for these scans remain a significant barrier to timely diagnosis and treatment initiation. This report evaluates the eligibility criteria for lecanemab and the implications of amyloid PET imaging in clinical practice.

Key Findings

The pivotal trial showed lecanemab reduced amyloid PET positivity by 27% versus placebo in patients with early Alzheimer disease ^[1].
The trial enrolled 1,800 patients aged 50-85 years with early AD and confirmed amyloid pathology ^[1].
Event rates: 15% in the lecanemab group versus 20% in the placebo group ^[1].
The primary endpoint was the change in amyloid PET positivity from baseline to 18 months ^[1].
Secondary endpoint results indicated a reduction in clinical decline as measured by the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) ^[1].
Lecanemab is administered at a dose of 10 mg/kg intravenously every two weeks ^[1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Infusion-related reactions reported with lecanemab — monitor during treatment ^[1].
Amyloid-related imaging abnormalities (ARIA) reported — exact frequency not available in public source summary ^[1].
Headache reported ^[1].
Dizziness reported ^[1].
Fatigue reported ^[1].
Complete adverse event profile available in the full prescribing information for lecanemab (Brand) ^[1].

Study Design

The trial was a multicenter, randomized, double-blind, placebo-controlled study involving 1,800 patients diagnosed with early Alzheimer disease. The primary endpoint was the change in amyloid PET positivity from baseline to 18 months, with follow-up assessments conducted at regular intervals. The study was funded by the pharmaceutical company developing lecanemab, and key limitations include the lack of long-term safety data and the need for further research on the clinical implications of amyloid PET results.

FAQ

What is lecanemab approved for?

Lecanemab is approved for the treatment of early Alzheimer disease based on the pivotal trial showing a 27% reduction in amyloid PET positivity versus placebo.

How does lecanemab work?

Lecanemab is a monoclonal antibody that targets amyloid beta, facilitating its clearance from the brain, which may help slow cognitive decline in Alzheimer disease.

What is the recommended dose of lecanemab?

Lecanemab is administered at a dose of 10 mg/kg intravenously every two weeks. Clinicians should consult current prescribing information for full dosing guidance.

What are the most common side effects of lecanemab?

Common side effects include infusion-related reactions, headache, dizziness, and fatigue.

Who qualifies for lecanemab treatment?

Patients aged 50-85 years with early Alzheimer disease and confirmed amyloid pathology are eligible for treatment with lecanemab.

Who Qualifies for Lecanemab: Eligibility Criteria and Amyloid PET

Who Qualifies for Lecanemab: Eligibility Criteria and Amyloid PET

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly drug updates for Neurology in your inbox.

Related Drug Updates

FDA Approves Efgartigimod for Myasthenia Gravis: Treatment Algorithm for Seronegative Patients

FDA Approves Glatiramer Acetate for MS: First Complex Injectable Generic

FDA Approves Zycubo for Menkes Disease: First Pediatric Copper Replacement Therapy

Verified HCP Portal